INTRODUCTION
In the United States, prostate cancer is the most common cancer and the third leading cause of cancer deaths in men, with an estimated 161,360 new cases annually (1) . Patients with metastatic prostate cancer initially respond to androgen deprivation therapy, but nearly all develop castration resistant disease (2) . Although recent therapeutic advances provide a survival benefit, not all patients respond, and those who do respond eventually develop resistance and experience disease progression (3) . Therefore, there is a need for improved therapies for patients with metastatic castration-resistant prostate cancer (mCRPC).
Prostate specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, has two known enzymatic functions. In the small intestine, it removes glutamates from dietary folates for absorption, and in the central nervous system, it hydrolyzes the most prevalent peptidic neurotransmitter, N-acetylaspartylglutamate (4) . PSMA is also expressed in renal tubule epithelium and normal prostate tissue, although the function of PSMA in these tissues is not well understood (4) . In contrast to the limited normal tissue expression at sites not accessible to an intact antibody (5) , PSMA is highly expressed in the epithelium of nearly all primary and metastatic prostate cancers (6) (7) (8) (9) and in the neovasculature that supplies most non-prostatic solid tumors, including carcinomas of the lung, colon, breast, kidney, liver, and pancreas as well as sarcomas and melanoma (10, 11) . It is a clinically validated tumor-associated antigen for imaging prostate cancer, and PSMA-targeted anti-cancer therapies involving multiple modalities have demonstrated early signs of clinical activity (12) (13) (14) (15) (16) (17) (18) .
Antibody drug conjugates (ADCs) consist of antibodies that specifically target tumor-associated antigens and are conjugated to small molecules that possess strong cytotoxic activity (19) .
Among the most potent cytotoxins are pyrrolobenzodiazepine (PBD) dimers, which can form highly cytotoxic DNA interstrand crosslinks (ICL) (20) . Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 31, 2018; DOI: 10.1158/1535-7163. vadastuximab talirine are in phase 3 studies in small cell lung cancer and acute myeloid leukaemia, respectively (22) . MEDI3726 (formerly known as ADCT-401, Figure 1) , is a PSMA-targeting ADC generated via site-specific conjugation of an engineered version of the anti-PSMA deimmunized (humanized) immunoglobulin G1 (IgG1) κ antibody J591 (23) to the PBD-based linker-drug tesirine (SG3249), which is the same PBD dimer used in rovalpituzumab tesirine (24) . MEDI3726 is under evaluation in a phase 1 clinical trial as an anticancer treatment in patients with mCRPC (NCT02991911). Herein we describe the in vitro and in vivo characterization of MEDI3726.
MATERIALS AND METHODS

Generation of ADCs
The antibody component of MEDI3726, J591, and the non-PSMA-targeting isotype control ADC contain the mutations C214S in the light chain and C226V and C229V in the heavy chain hinge (antibody numbering herein is according to EU numbering) (25) . These mutations allow the site-specific conjugation of maleimide at position C220 with the drug linker tesirine. The conjugation procedure and the analytical characterization of MEDI3726 as well as the generation and purification of the soluble recombinant extracellular PSMA domains (sPSMA) for human (shPSMA), cynomolgus monkey (Macaca fascicularis, scPSMA), and rat (srPSMA) are described in the Supplementary Methods section.
Two monomethyl auristatin E (MMAE)-based ADCs targeting PSMA (PSMA-ADC1-MMAE and PSMA-ADC2-MMAE) were generated as described in patent US 8114965 B2 by Concortis (San Diego, USA).
Competitive ELISA to Determine Species Cross-Reactivity
The ability of each sPSMA to displace MEDI3726 from shPSMA was determined by competitive ELISA. Briefly, Maxisorp microplates (Nunc) were coated with shPSMA (50 L/well, 1.0 μg/mL in PBS) and incubated at 4°C overnight. A 2-fold dilution series of each sPSMA antigen was dispensed (50 L/well, in PBS/Tween/BSA (PBS 0.05%, Tween 20 (v/v), 2% BSA (w/v)). MEDI3726 was then added (50 L / well of 0.2 g/mL in PBS/Tween/BSA) and incubated for 1 h at room temperature (RT). After the MEDI3726-shPSMA complex was washed, 50 L of goat antihuman immunoglobulin G (IgG)-horseradish peroxidase (HRP) conjugate (Jackson Immunoresearch) (diluted 1:1000 in PBS/Tween/BSA) was added and incubated for 1 h at RT. After the wash, TMB-Turbo (Thermo Fisher Scientific) was added (75 μL/well) and the reaction was stopped with hydrochloric acid (HCl) (75 μL/well, 0.6 M). Well optical densities were measured on the EnVision plate reader (PerkinElmer) at 450 nm and data were analyzed by using GraphPad Prism (GraphPad Software, Inc.).
In Vitro Characterization of PSMA Expression and MEDI3726 Activity
The LNCaP, CWR22Rv1, MDA PCa 2b, PC-3, and DU145 prostate cancer cell lines were obtained from American Type Culture Collection (ATCC) and maintained by following ATCC recommendations. The authentication of these mycoplasma negative lines was performed by ATCC to verify the identity of human cell lines and to rule out both intra-and interspecies contamination. The cell lines used in the assays were not re-authenticated or tested at ADC Therapeutics, but they were passaged for fewer than 6 months after the initiation of culture. The The cytotoxicity of SG3199, MEDI3726, and the non-targeted isotype control ADC was measured in each cell line after an incubation period ranging from 5 to 7 days at 37°C and 5% carbon dioxide. This incubation period was calculated to be at least three normal cell doubling times and was used for exposure to either warhead toxin or ADCs. After the ADC exposure period, cell viability was measured with the CellTitreGlo assay (Promega) following the manufacturer's protocol. IC 50 values were calculated by using GraphPad to fit luminescence data to a sigmoidal dose-response curve with variable slope.
MEDI3726 Internalization and Lysosomal Trafficking
Immunofluorescence microscopy was used to detect internalization and colocalization of MEDI3726 or an isotype control ADC with the lysosomal marker, lysosome-associated membrane protein 1 (LAMP1). One cell line demonstrated to be PSMA positive and one demonstrated to be PSMA negative were incubated with MEDI3726 or the isotype control ADC.
A detailed protocol is provided in the Supplementary Methods.
Single Cell Gel Electrophoresis (Comet) Assay
The modified single-cell gel electrophoresis (Comet) assay as described by Hartley et al (26) was used to monitor the formation of DNA ICLs generated by the SG3199, MEDI3726, or the nontargeting isotype control ADC and the unhooking step of repair of these ICLs. Briefly, 10 5 cells were seeded in 24-well plates and treated with MEDI3726 (6 nM), isotype control ADC (4.7 nM, an equimolar PBD concentration) or SG3199 (2.5 nM) for 2 h, washed, and incubated with drugfree culture medium for the required posttreatment time (up to 36 h). At each time point, cells were harvested and stored at -80°C until they were used. Except for non-irradiated controls, thawed samples (3x10 4 cells/mL) were irradiated (15 Gy) to introduce a fixed number of random DNA strand breaks and then processed for the Comet assay. The Olive Tail Moment (OTM) was determined as described previously (27) , using the formula: where TMdi is the tail moment of drug-treated, irradiated sample; TMcu is the tail moment of untreated, non-irradiated control; and TMci is the tail moment of untreated, irradiated control.
Crosslinking was expressed as the percentage decrease in the OTM compared with control irradiated cells.
Determination of the In Vivo Activity of MEDI3726 in LNCaP, CWR22Rv1, and PC-3
Xenograft Models
The LNCaP xenograft study was performed by Crown Bioscience, United Kingdom, according to ethical standards and practice. LNCaP cells (5x10 6 ) were implanted subcutaneously with were randomized (based on tumor volume) into study groups (n=10) and the treatment was initiated (Day 1). Mice were eleven weeks old with a body weight range of 17.5 g to 27.6 g on Day 1 of the study. In the CWR22Rv1 and PC-3 studies, each animal was euthanized when its tumor volume exceeded 1,000 mm 3 , or on the final day (Day 94 for the CWR22Rv1 study and Day 60 for the PC-3 study), whichever came first.
All dosing materials were administered intravenously as a single dose except for the MMAEbased PSMA-targeted ADCs, which were administered once every 4 days for six doses total.
Both tumor and body weight measurements were collected twice weekly, and the tumor volume was calculated using the formula:
Statistical analysis is described in the Supplementary Methods.
Determination of In Vivo Activity of MEDI3726 in LuCaP PDX Models
The LuCaP 35CR, 58, 70, 73, 77, 86.2, 96CR and 147 prostate cancer PDX models were used (29) . LuCaP 35CR and LuCaP 96CR are castration-resistant models established and maintained in castrated male mice (29) . All LuCaP models used in this study express differing levels of androgen receptor (AR) splice variant AR-V7, and LuCaP 86.2 model expresses the AR-V567es variant (30, 31) . randomized (based on tumor volume) into study groups of 6 mice per group. The body weight of mice ranged from 21.1 g to 25.5 g at the initiation of dosing. MEDI3726 was given intravenously at doses of 0.1, 0.3, or 0.9 mg/kg, and the isotype control ADC was given at a dose of 0.9 mg/kg. Both ADCs were administered intravenously once every 3 weeks for three doses according to body weight. Tumor and body weight measurements, and the statistical analysis were carried out as described above. Statistically significant differences were determined by using one-way ANOVA with posthoc Tukey for the multiple comparison. GraphPad Prism 7 was used for statistical analyses.
Immunohistochemistry of Tumor Xenografts
RESULTS
MEDI3726
MEDI3726 had a monomer content of 98% as determined by size-exclusion chromatography (SEC) and a drug to antibody ratio (DAR) as measured by reduced liquid chromatography mass spectrometry (LCMS), close to 2. Both shPSMA and scPSMA competed for binding of MEDI3726 to shPSMA with similar half-maximal effective concentrations of 17.92 ng/mL and 16.89 ng/mL, respectively (Table 1) . However, srPSMA did not compete for binding to MEDI3726, indicating a lack of rodent cross-reactivity for J591. As demonstrated by surface plasmon resonance, MEDI3726 bound to shPSMA and scPSMA with similar affinities of 1.67 nM and 3.11 nM, respectively, consistent with the competitive ELISA data (Table 1) .
MEDI3726 maintained activity for up to 7 days in PBS or human or cynomolgus monkey plasma at 37°C as determined by in vitro cytotoxic activity on LNCaP cells, binding to sPSMA and determination of PBD containing ADC by anti-PBD antibody capture assays (Supplementary Figure S1 ).
In Vitro Characterization of PSMA Expression and Activity of MEDI3726
The LNCaP and LNCaP C4-2 prostate cancer lines had the highest antigen densities, whereas PC-3 and DU145 had antigen densities below the lower limit of quantitation (7, 348) for the assay and were therefore classified as PSMA-negative ( Table 2 ). More than 90% of LNCaP, LNCaP C4-2, and MDA PCa 2b cells were positive for PSMA expression, but fewer than half of the CWR22Rv1 cells were PSMA-positive (Table 2) . Table 2) .
Internalization and DNA Crosslinking
Cellular internalization and trafficking of MEDI3726 to the lysosome are essential for SG3199 to be released from other tesirine components by cleavage of the valine-alanine dipeptide linker. Figure 2B ). The isotype control ADC did not bind and was not internalized by LNCaP or PC-3 cells ( Figures 2C and 2D , respectively).
Immediately after LNCaP cells were incubated with MEDI3726, a low level of DNA crosslinking (5%) was observed and increased with time to a peak level of approximately 50% at 24 h, which persisted at 36 h ( Figure 2E ). SG3199 induced ICLs more rapidly, with approximately 35% observed at the end of the incubation period and a peak of more than 60% by 6 h. Peak level of crosslinking induced by SG3199 also persisted at 36 h. The lower level of and longer time to maximum ICL formation by MEDI3726 likely arose from differential uptake and an extra processing hurdle of MEDI3726 to release the payload compared to SG3199 which can diffuse across the membrane and crosslink DNA without processing.
In the PSMA-negative cell line PC-3, MEDI3726 did not produce a significant level of DNA ICLs over 36 h ( Figure 2F ). However, SG3199 produced a high level of ICLs, similar to that observed in the LNCaP cell line. These results are consistent with the target-mediated internalization and cell killing by MEDI3726.
In Vivo Activity of MEDI3726 in Prostate Cancer Cell Line Xenografts
As determined by IHC, PSMA expression in the LNCaP xenografts was homogeneous, with nearly all tumor cells staining strongly positive for PSMA ( Figure 3A ). In this model, MEDI3726 showed a dose-dependent antitumor activity ( Figure 3B) , with an extended tumor stasis preceding regrowth after a single dose of 1 mg/kg, and a significant increase in the time-toendpoint (TTE) survival, compared with all other groups ( Supplementary Table S1 ).
Additionally, MEDI3726 was associated with a statistically significant increase in animal survival, compared with the naked antibody group, at 0.33 mg/kg and 1 mg/kg ( Supplementary   Table S1 ). The non-targeting isotype control ADC was also associated with a statistical increase in survival compared with the control groups, but only at the highest dose of 1 mg/kg (Supplementary Figure S2 and Table S1 ). Next, we investigated MEDI3726 in CWR22Rv1 xenografts, castration-resistant model (28) .
IHC analysis of the CWR22Rv1 xenograft tumors confirmed the heterogeneous expression of
PSMA in this model, with approximately 20% to 50% of tumor cells staining positive for PSMA ( Figure 3C , Supplementary Table S2 ). Administration of MEDI3726 resulted in a dosedependent antitumor activity ( Figure 3D) , with a prolonged tumor regression (approximately 50 days) after a single 1 mg/kg dose ( Supplementary Table S3 ). A single dose of the isotype control ADC at 0.75 mg/kg resulted in tumor growth comparable with that seen in vehicle-treated animals (Supplementary Figure S3) . Notably, two monomethyl auristatin E-based, PSMAtargeted ADCs, PSMA-ADC1-MMAE (DAR = 4) and PSMA-ADC2-MMAE (DAR = 4), did not show antitumor activity at 3 mg/kg or 6 mg/kg. Nor did these ADCs show in vitro cytotoxic activity in CWR22Rv1 cells, although they did bind to PSMA positive cells and showed strong cytotoxic activity on LNCaP cells (Supplementary Figure S4) .
In the PC-3 xenograft model, which did not express PSMA ( Figure 3E ), administration of MEDI3726 and the isotype control ADC resulted in limited antitumor activity at the highest dose (1 mg/kg) ( Figure 3F , Supplementary Table S4 ). This result might have occurred because of nontarget-specific uptake of the ADCs by the tumor cells and/or local release of PBD toxin caused by tumor associated macrophages (32) .
In vivo activity of MEDI3726 in LuCaP prostate cancer PDX models
To further characterize the in vivo activity of MEDI3726, we assessed the efficacy of MEDI3726 against a panel of clinically relevant LuCaP prostate cancer PDX models. Among eight LuCaP models, six (LuCaP 70, 73, 77, 86.2, 96CR, 147) showed strong membrane expression of PSMA in more than 75% of tumor cells, as determined by IHC ( Figure 4A and Supplementary Table   S2 ). Of the remaining two, LuCaP 58 showed moderate PSMA staining intensity in 10% to 25% of tumor cells and LuCaP 35CR was negative for PSMA. Consistent with the results in the cell line xenografts, highly PSMA-positive LuCaP models responded in a dose-dependent manner to MEDI3726 (Figure 4 Next, we sought to investigate the phosphorylation of Histone H2AX (-H2AX), which occurs following the DNA damage induced by SG3199-generated ICLs. Tumors were collected from the LuCaP 73 xenograft bearing mice 48 hours after the first single administration of each ADC.
A dose-related increase in the number of -H2AX-positive nuclei was observed among each of the MEDI3726 treatment groups, compared with both the control and isotype control groups.
However, statistical significance was achieved only at the highest MEDI3726 dose tested ( Figure   4J and Supplementary Figure S5 ). It is important to note that the collection time point at 48 hours post single dose may not have been optimal to detect the differences in -H2AX positive cells between the two lower dose levels, given that the tumor regression was not observed until the second dose of 0.3 mg/kg of MEDI3726. Figure S6) . As noted earlier, MEDI3726 does not bind to rodent PSMA.
MEDI3726 related toxicity, as determined by body weight measurements, was not observed in any of the cell line xenograft and PDX model studies (Supplementary
Toxicology of MEDI3726 in Cynomolgus Monkey
Cynomolgus monkey was selected as a relevant species for the toxicity study after MEDI3726 demonstrated comparable cross-reactive binding activity to human and cynomolgus monkey PSMA as determined by BIAcore (SPR) and competitive ELISA assays ( Figure S7 ). Dose-dependent (late onset) reversible black skin discoloration, correlating with epidermal hyperpigmentation and hyperplasia was observed as well as reversible microscopic changes in lymphoid organs (decreased or absent germinal centers) and kidney (tubular degeneration, cellular hypertrophy/atypia, focal inflammation, and edema). Changes in the testis (seminiferous tubule degeneration, vacuolation, reduced sertoli cells and loss of germ cells) were not fully recoverable during the study, but the presence of intact spermatogonia in the testis supported that full recovery would be evident with time (33) . The Highest Non-Severely Toxic Dose (HNSTD), was the highest dose tested of 0.6 mg/kg.
DISCUSSION
MEDI3726 is a PSMA-targeting ADC generated via site-specific conjugation of an engineered version of the J591 antibody to the PBD-based linker-drug tesirine. In vitro, MEDI3726 demonstrated potent and specific cytotoxic activity. In the CWR22Rv1 cell line, where approximately 40% of the cells were positive for PSMA expression, MEDI3726 demonstrated potent in vitro activity, with close to 100% of the cells being killed. This maximum cell kill was likely achieved via bystander activity, which has been reported for other ADCs using tesirine (27, 34, 35) . In agreement with the potent in vitro activity observed with the CWR22Rv1 cell line, As part of the Investigational New Drug Application enabling studies, MEDI3726 was tested in a repeat-dose, intravenous, GLP study in cynomolgus monkeys. The major adverse effects following administration of MEDI3726 were related primarily to the known safety profile previously reported in a phase 1 study of an ADC containing the same linker-drug teserine (38) and were consistent with the profile associated with the mechanism of action of the PBD dimer warhead. The major dose-limiting toxicity associated with MEDI3726 was myelosuppression, but this effect was readily monitorable. Overall, the toxicology profile of MEDI3726 supported further study of the drug in phase 1 clinical trials.
PSMA is a well-characterized tumor associated antigen for prostate cancer and possesses many features that make it attractive for an ADC-mediated targeting approach to mCRPC. Two PSMA-targeting ADCs using tubulin-inhibiting payloads have been investigated in clinical studies in patients with mCRPC (16, 39) . MLN2704, an ADC utilizing the unmodified J591 anti-PSMA antibody, has shown a limited therapeutic window in a Phase 1/2 study in mCPRC patients attributed to the unstable disulfide linker, leading to rapid deconjugation of the DM1 warhead after administration to patients (39) . PSMA ADC has demonstrated anti-tumor activity in a Phase 2 study in patients with mCRPC based on radiological response and reductions in circulating tumor cells and prostate-specific antigen (16) . While neither of these tubulin inhibitor based ADCs is under current clinical development, MEDI3726 is the first PSMA targeting ADC utilizing the highly potent DNA crosslinking PBD payload tesirine in clinical development for mCRPC (NCT02991911).
Preclinical studies have demonstrated that reduced expression of BRCA1 or BRCA2, key components of the homologous recombination (HR) pathway involved in the repair of PBD mediated DNA damage, increases the sensitivity of tumor cells to PBD-mediated cell death (40, 41) . Notably, recent data have shown that mutations in DNA repair pathway genes occur in 20% to 25% of prostate cancer cases (42 expression of PSMA, but also decreases the expression of genes involved in the HR pathway (43, 44) .
In conclusion, the emerging data showing frequent mutations of DNA damage response (DDR) genes in prostate cancer together with the decreased DDR gene expression induced by pharmacological suppression of the AR pathway provide a strong rationale for targeting prostate cancer with MEDI3726, which combines specific targeting of highly expressed prostate cancer tumor antigen PSMA with a potent DNA damage inducer, not only as monotherapy, but also in conjunction with AR pathway inhibitors. Note: The cytotoxicity of SG3199, MEDI3726, and the isotype control ADC was determined by CellTitreGlo assay. n = 3; NA = not applicable; Negative = below the lower limit of quantitation (7, 348 
